CCHD, the screen without a blood spot

The federal Recommended Uniform Screening Panel was built around the dried blood spot. The chemistry of the assays evolved (immunoreactive trypsinogen for cystic fibrosis, tandem mass spectrometry for the metabolic conditions, enzyme activity for the lysosomal storage disorders), but the substrate stayed the same. Critical congenital heart disease is the exception. The CCHD screen is pulse oximetry on a baby's foot. The instrument is a saturation probe, not a centrifuge. The condition was added to the federal panel in 2011 anyway, because the case for doing so was overwhelming.

What CCHD is

Critical congenital heart disease is a clinical category, not a single disorder. The category includes the cardiac malformations severe enough to require surgical or catheter-based intervention in the first year of life. The list typically includes hypoplastic left heart syndrome, transposition of the great arteries, tetralogy of Fallot, total anomalous pulmonary venous return, truncus arteriosus, tricuspid atresia, pulmonary atresia, and several other conditions. The unifying clinical feature is that intervention is required in early infancy and that delay can be lethal.

CCHD affects roughly 2 per 1,000 live births in the United States. The conditions are diagnosed prenatally in some cases through routine fetal ultrasound, particularly in the second-trimester anatomy survey, but prenatal detection rates remain incomplete. Some lesions are difficult to visualize antenatally. Many pregnancies, particularly in lower-resourced settings, do not include a detailed cardiac fetal ultrasound. Newborn cardiac examination by physical examination alone, without imaging, misses a substantial fraction of CCHD because the typical timing of clinical presentation is after the postnatal closure of the ductus arteriosus, which can happen days to weeks after birth.

The clinical event that universal screening prevents is the postnatal cardiovascular collapse that follows ductal closure in a duct-dependent lesion. Without intervention, the infant can decompensate suddenly and die before the underlying cardiac defect is recognized.

How the screen works

Pulse oximetry measures arterial oxygen saturation noninvasively. The CCHD screen is performed at 24 to 48 hours of life. A saturation probe is placed on the baby's right hand (preductal) and on either foot (postductal). A positive screen is defined by a saturation below a threshold (typically 90 percent on either site, or a difference of more than 3 percent between hand and foot, or a saturation between 90 and 94 percent on repeat measurements over an hour). A positive screen prompts cardiology evaluation including echocardiography.

The screen identifies most ductal-dependent lesions because the abnormal mixing of pulmonary and systemic circulations produces measurable hypoxia. Some lesions, including coarctation of the aorta and certain forms of left-sided obstruction, can produce normal saturations and are missed. Sensitivity for the targeted lesions is high but not perfect. Specificity is high enough that false-positive rates are manageable with the standard threshold protocol.

Implementation in the United States rolled out from 2011 onward. The Health Resources and Services Administration provides national guidance and tracks state adoption. All US states now mandate or recommend pulse oximetry screening for CCHD. International adoption has been broad. Several large studies, including the published New Jersey, California, and UK cohorts, have documented reductions in late presentation, postneonatal mortality from CCHD, and emergency room presentations of duct-dependent lesions after the screen was implemented.

What management looks like

Management of an individual CCHD is specific to the lesion. The shared early management is preserving ductal patency with intravenous prostaglandin E1 until the lesion is anatomically defined and a surgical or catheter-based plan is in place. Fetal cardiology programs at major pediatric centers manage the antenatal-to-postnatal handoff for prenatally diagnosed cases. For postnatally diagnosed cases, transfer to a tertiary cardiac center with neonatal cardiac surgical capability is the typical pathway.

Surgical or catheter-based interventions in the first weeks of life have transformed the outcome of most CCHDs. Hypoplastic left heart syndrome, near-uniformly fatal in the 1970s, now has a multistage palliation pathway with substantial proportions of survivors reaching adulthood. Transposition of the great arteries, similarly fatal before the arterial switch operation became standard, now has near-normal survival and acceptable long-term outcomes after the switch. The other ductal-dependent lesions follow similar trajectories.

Lifelong follow-up in a congenital cardiology program is standard. Adult congenital heart disease is now its own subspecialty because the population of survivors has grown into a cohort that pediatric cardiology was not built to follow.

What this looks like for a family

A baby is born. At 24 hours of life, the saturation probe is placed. The hand reads 99 percent. The foot reads 89 percent. The repeat at one hour confirms the gradient. Cardiology is called. Echocardiography shows hypoplastic left heart syndrome. Prostaglandin is started. Within hours, the baby is on a transport team to a pediatric cardiac center. The Norwood procedure is performed in the first week of life. Six months later, the second-stage Glenn procedure. Two to three years later, the Fontan completion.

That child grows up under cardiology surveillance. Activity is modified to her cardiovascular reserve. Adolescence and adulthood bring new questions about exercise tolerance, pregnancy, and long-term cardiac function. The medicine is harder than the screen. The screen is what made the medicine possible.

That is what CCHD care looks like in practice. A two-minute saturation reading at 24 hours of life identifies the catastrophic event that historically killed an infant in the second week. Everything afterward is the work of pediatric and adult congenital cardiology.